| 1 |
Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy |
|
| | Vikas Jhawat,Monika Gulia,Sumeet Gupta,Balaji Maddiboyina,Rohit Dutt | | | Journal of Controlled Release. 2020; 327: 500 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Carbamazepine adverse drug reactions |
|
| | Ingrid Fricke-Galindo,Adrián LLerena,Helgi Jung-Cook,Marisol López-López | | | Expert Review of Clinical Pharmacology. 2018; : 1 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Genetic polymorphisms associated with circadian rhythm dysregulation provide new perspectives on bipolar disorder |
|
| | Thomaz Oliveira,Victor Marinho,Valécia Carvalho,Francisco Magalhăes,Kaline Rocha,Carla Ayres,Silmar Teixeira,Monara Nunes,Victor Hugo Bastos,Giovanny R Pinto | | | Bipolar Disorders. 2018; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients |
|
| | Tatiana Tverdohleb,Bora Dinc,Ivana Knezevic,Kenneth D. Candido,Nebojsa Nick Knezevic | | | Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1 | | | [Pubmed] [Google Scholar] [DOI] | |
|
